Aetna Modified Tumor Marker Coverage Policy CPB 0352 — What Billing Teams Need to Know in 2026

TL;DR: Aetna, a CVS Health company, modified CPB 0352 governing tumor marker testing coverage, effective February 14, 2026. This policy update affects oncology and laboratory billing teams who submit tumor marker claims to Aetna. The policy does not list specific codes in the available data — audit your current charge capture against the updated criteria before submitting new claims.

Tumor markers sit in one of the highest-scrutiny zones in oncology billing. Aetna's coverage policy for these tests has long been a source of claim denials, largely because medical necessity documentation requirements are strict and the line between covered monitoring and non-covered screening is narrow. This modification to CPB 0352 in the CPB 0352 Aetna system is a signal to review how your team documents and bills these services right now — before denials start showing up in your AR.

Quick-Reference Table

Aetna Tumor Marker Coverage Criteria and Medical Necessity Requirements 2026

The Aetna tumor marker coverage policy under CPB 0352 draws a hard line between two clinical uses: monitoring known cancer and screening for cancer in asymptomatic patients. Aetna generally covers tumor markers for monitoring response to treatment, detecting recurrence, and staging in patients with a confirmed diagnosis. Screening use — ordering a tumor marker in a patient without a prior confirmed malignancy — is where most claims fall apart.

Medical necessity is the controlling standard here. Aetna requires that tumor marker testing be ordered in response to a specific clinical indication tied to an established diagnosis. A vague order for "cancer surveillance" without documented clinical context will not meet medical necessity under this coverage policy. Your ordering physicians need to connect the dots in the medical record — diagnosis, clinical question, how the result will change management.

Prior authorization requirements for tumor markers vary by plan type under Aetna. Some commercial plans require prior auth for repeat or serial testing. Check the specific member's benefit plan before assuming blanket coverage. If you're billing high-volume serial markers — CEA every three months post-resection, for example — prior authorization may be a condition of reimbursement on certain Aetna products.

The real issue with tumor marker billing under any payer is frequency. A single baseline test at diagnosis is rarely the problem. It's the ongoing serial testing where denials cluster. Aetna's CPB 0352 has historically required clinical justification for each testing episode, not just the initial order. This modification likely refines those frequency and indication criteria — which means your billing team should treat every serial order as a separate medical necessity determination, not a standing order.

Aetna Tumor Marker Exclusions and Non-Covered Indications

Aetna has consistently treated tumor markers used for population-based cancer screening as not medically necessary under this coverage policy. This applies to commonly ordered markers like PSA in low-risk patients without symptoms, CA-125 in women without a prior diagnosis or high-risk genetic profile, and CEA ordered outside of a confirmed colorectal cancer context.

Tumor markers ordered for general wellness panels or bundled into executive physicals are a known denial trigger. These don't meet medical necessity because there's no active clinical question tied to a confirmed diagnosis. If your practice manages employer wellness programs or concierge panels, this is a direct financial exposure.

Investigational or experimental indications are another exclusion category in CPB 0352. Newer liquid biopsy markers and certain circulating tumor DNA (ctDNA) panels occupy gray area here. Aetna has been slow to move novel biomarkers from experimental to covered status. If your oncology team is ordering next-generation tumor marker panels — beyond the traditional AFP, CEA, CA 19-9, CA-125, PSA tier — check CPB 0352 directly before billing. An experimental designation means zero reimbursement, and those denials are not typically overturned on appeal without a policy change.

Coverage Indications at a Glance

The specific codes and indication-level criteria for CPB 0352 are not available in the current policy data. The table below reflects the general framework Aetna applies under this coverage policy. Confirm each row against the full CPB 0352 document before making billing decisions.

Aetna Tumor Marker Billing Guidelines and Action Items 2026

The effective date of February 14, 2026 is already here. If your team hasn't reviewed workflows against the modified CPB 0352, start now.

CPT, HCPCS, and ICD-10 Codes for Tumor Markers Under CPB 0352

The available policy data for CPB 0352 does not include a specific list of CPT, HCPCS, or ICD-10 codes. Aetna's full CPB 0352 policy document contains the complete code list. Access the current version of CPB 0352 directly at the Aetna provider policy library or through app.payerpolicy.org/p/aetna/0352 to pull the authoritative code set.

Common tumor marker CPT codes that typically appear in policies of this type — such as codes for CEA, AFP, CA-125, CA 19-9, and PSA testing — are not confirmed in the available data for this modification. Do not use any code list that was not pulled directly from the current CPB 0352 document. An outdated code reference is worse than no reference at all when you're filing claims.

Once you access the full policy, organize the codes by coverage status — covered when criteria are met, not covered, and experimental. Your billing team should map those codes against your current charge description master (CDM) to identify any gaps before the next claim submission cycle.